Greenspring Advisors’s Pfizer PFE Stock Holding History

Greenspring Advisors’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,274	Closed	-$260K	–	360
2026 Q1	$260K	Buy	+9,274	New	+$247K	0.02%	262
2022 Q1	–	Sell	-6,651	Closed	-$393K	–	120
2021 Q4	$393K	Buy	+6,651	New	+$330K	0.1%	70

Other funds holding PFE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Greenspring Advisors's PFE Position: Q2 2026 in Review

Greenspring Advisors sold out of Pfizer (PFE) in Q2 2026, closing a stake of 9,274 shares — an estimated $260K sold.

Greenspring Advisors first reported a position in PFE in Q4 2021 and held it in 2 quarters. The position peaked at $393K in Q4 2021. 2,822 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

Greenspring Advisors reported no remaining Pfizer position as of Q2 2026 after selling out during the quarter.
Greenspring Advisors sold 9,274 Pfizer shares in Q2 2026, an estimated $260K.
Greenspring Advisors first reported a position in Pfizer in Q4 2021 and held it in 2 quarters.
Greenspring Advisors's Pfizer position peaked at $393K in Q4 2021.
2,822 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Greenspring Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.